

# Rosa Daniela Grembiale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2556725/publications.pdf>

Version: 2024-02-01

55  
papers

1,368  
citations

279798

23  
h-index

361022

35  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2010  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 180.	2.4	4
2	Fatigue and Associated Factors in an Immune-Mediated Inflammatory Disease Population: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2455.	2.4	4
3	Satisfaction with Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 177-186.	0.8	2
4	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. <i>Clinical Rheumatology</i> , 2021, 40, 2251-2262.	2.2	10
5	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	5.8	38
6	Psychometric evaluation of an Italian custom 4-item short form of the PROMIS anxiety item bank in immune-mediated inflammatory diseases: an item response theory analysis. <i>PeerJ</i> , 2021, 9, e12100.	2.0	6
7	A Biomechatronic Device Actuated by Pneumatic Artificial Muscles for the Automatic Evaluation of Nociceptive Thresholds in Rheumatic Patients. <i>Actuators</i> , 2020, 9, 78.	2.3	1
8	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	3.5	38
9	Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 787-798.	3.1	6
10	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , 2020, 15, e0235326.	2.5	31
11	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	3.5	40
12	Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. <i>Journal of Rheumatology</i> , 2019, 46, 904-911.	2.0	58
13	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 864-872.	2.0	70
14	Mouse models of multiple myeloma: technologic platforms and perspectives. <i>Oncotarget</i> , 2018, 9, 20119-20133.	1.8	35
15	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. <i>Rheumatology</i> , 2018, 57, vii23-vii31.	1.9	9
16	Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). <i>PLoS ONE</i> , 2018, 13, e0205134.	2.5	9
17	Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence. <i>Open Access Rheumatology: Research and Reviews</i> , 2018, Volume 10, 129-134.	1.6	1
18	Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives. <i>Current Medicinal Chemistry</i> , 2018, 25, 3096-3104.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: A Case-Control Study. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 215-221.	0.8	4
20	Insulin-Sensitizing Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 184-191.	0.8	11
21	Kaposi's sarcoma after T-cell costimulation blockade with abatacept in rheumatoid arthritis: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 367-369.	1.5	6
22	Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 5346.	3.3	62
23	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq1 1 0.784314 rgBT /Overlock 11</i>	3.8	107
24	Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. <i>European Journal of Clinical Investigation</i> , 2017, 47, 728-735.	3.4	26
25	High Prevalence of Achilles Tendon Enthesopathic Changes in Patients with Type 2 Diabetes Without Peripheral Neuropathy. <i>Journal of the American Podiatric Medical Association</i> , 2017, 107, 99-105.	0.3	19
26	Plantar fascia enthesopathy is highly prevalent in diabetic patients without peripheral neuropathy and correlates with retinopathy and impaired kidney function. <i>PLoS ONE</i> , 2017, 12, e0174529.	2.5	12
27	Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 124-128.	0.8	13
28	Serum complement C3 strongly correlates with whole-body insulin sensitivity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 18-23.	0.8	15
29	Complement C3 Is the Strongest Predictor of Whole-Body Insulin Sensitivity in Psoriatic Arthritis. <i>PLoS ONE</i> , 2016, 11, e0163464.	2.5	13
30	Correlation between elastosonography and nailfold microvascular alterations in systemic sclerosis patients. <i>Clinical Hemorheology and Microcirculation</i> , 2016, 62, 71-78.	1.7	3
31	Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2016, 95, e2552.	1.0	48
32	Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis cohort from southern Italy: Comment on "Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study" by Tseng et al., <i>Joint Bone Spine</i> 2016;83:307-313. <i>Joint Bone Spine</i> , 2016, 83, 611-612.	1.6	15
33	Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1892-1894.	0.7	23
34	Use of sonoelastography to evaluate texture modifications of mozzarella di bufala campana D.O.P. during storage at different temperatures. <i>Italian Journal of Food Safety</i> , 2015, 4, 4746.	0.8	1
35	Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2015, 94, e888.	1.0	61
36	Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. <i>Clinical Rheumatology</i> , 2014, 33, 1759-1764.	2.2	27

#	ARTICLE	IF	CITATIONS
37	Abatacept in psoriatic arthritis: Case report and short review. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S29-S32.	0.4	20
38	Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. <i>Advances in Pharmacological Sciences</i> , 2013, 2013, 1-8.	3.7	30
39	Improvement in insulin resistance after short-term treatment with abatacept: case report and short review. <i>Clinical Rheumatology</i> , 2012, 31, 1401-1402.	2.2	24
40	Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 485-491.	2.6	26
41	Update on optimal use of omalizumab in management of asthma. <i>Journal of Asthma and Allergy</i> , 2011, 4, 49.	3.4	51
42	Fibromyalgia and obesity: the hidden link. <i>Rheumatology International</i> , 2011, 31, 1403-1408.	3.0	121
43	Infliximab and insulin resistance. <i>Autoimmunity Reviews</i> , 2010, 9, 536-539.	5.8	27
44	CD4+ T-cells lymphocytosis and reduction of neutrophils during treatment with adalimumab: Challenge and dechallenge study. <i>Clinical Immunology</i> , 2010, 135, 499-500.	3.2	7
45	Sudden Progression from Impaired Glucose Tolerance to Type 2 Diabetes after Discontinuation of Administration of Anti-Tumor Necrosis Factor-Alpha Antibody Infliximab. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 961-963.	2.1	15
46	Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab. <i>International Immunopharmacology</i> , 2010, 10, 827-828.	3.8	34
47	Effect of interaction between left ventricular dysfunction and endothelial function in hypertension. <i>Current Hypertension Reports</i> , 2006, 8, 212-218.	3.5	9
48	Effects of Transforming Growth Factor- $\beta$ 2 and Budesonide on Mitogen-Activated Protein Kinase Activation and Apoptosis in Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 29, 12-18.	2.9	53
49	Methimazole-Induced Asthma?. <i>Chest</i> , 2002, 121, 305-306.	0.8	1
50	Comparison of the Bronchodilating Effects of Inhaled Formoterol, Salmeterol and Salbutamol in Asthmatic Patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2002, 15, 463-466.	2.6	15
51	A single-blind, partial crossover clinical trial of the effects of inhaled fluticasone propionate and nedocromil sodium on airway hyperresponsiveness to methacholine. <i>Current Therapeutic Research</i> , 2002, 63, 316-327.	1.2	1
52	Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. <i>Life Sciences</i> , 2002, 70, 977-990.	4.3	52
53	Bronchial Asthma Induced by an Antithyroid Drug. <i>Chest</i> , 2001, 119, 1598-1599.	0.8	13
54	Effects of glucocorticoids on activation of c-jun N-terminal, extracellular signal-regulated, and p38 MAP kinases in human pulmonary endothelial cells. Abbreviations: AP-1, activator protein-1; Dex, dexamethasone; ERK, extracellular signal-regulated kinases; GCS, glucocorticosteroids; GR, glucocorticoid receptors; H <sub>2</sub> O <sub>2</sub> , hydrogen peroxide; HMVEC-L, human microvascular endothelial cells from lung; IL-1 $\beta$ , interleukin-1 $\beta$ ; JNK, c-jun N-terminal kinases; MAPK, mitogen-activated protein kinases; Test testosterone;. <i>Biochemical Pharmacology</i> , 2001, 62, 1719-1724.	4.4	26

#	ARTICLE	IF	CITATIONS
55	Snail ingestion and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1996, 51, 361-361.	5.7	9